INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
Delivering Cell & Gene Therapeutics
181
Issue No #181 Dec 2025
December 17th, 2025
Download PDF
Issue 181 - Dec 2025
Inside the magazine
PREFILLED SYRINGES
Hiroki Hasegawa
Mitsubishi Gas Chemical
USING OXYCAPT™ MULTILAYER PLASTIC VIAL FOR GENE AND CELL THERAPIES STORED IN DRY ICE AND LIQUID NITROGEN
Hiroki Hasegawa and Tomohiro Suzuki consider the various challenges presented by cold-chain logistics to both traditional glass vials and many cyclo-olefin polymer alternatives, and how Mitsubishi Gas Chemical's OXYCAPT™ vials offer significant advantages for maintaining container closure integrity compared with other materials on the market.
CGT
Krishnendu khan
West Pharmaceutical Services
PRIMARY PACKAGING AND ADMINISTRATION OF CELL THERAPIES: CURRENT TRENDS AND CHALLENGES
Dr Krishnendu Khan and Henry Nguyen of West Pharmaceutical Services examine factors to consider when designing and selecting primary packaging for cell therapies, exploring the effects of cryogenic storage on packaging and cells, while highlighting the diverse delivery methods and applications for these therapies.
CGT
Dr Laure-Helene Guillemot
Aptar Pharma
EVOLVING ELASTOMER STOPPER TECHNOLOGIES FOR A CHANGING REGULATORY LANDSCAPE
Dr Laure-Hélène Guillemot and Edouard Pagnoud assess the impact of the per- and polyfluoroalkyl substances ban on elastomer stoppers and the resulting extractables and leachables challenges, highlighting how Aptar Pharma is developing new solutions to meet both regulatory expectations and customer needs.
CGT
Hanna Beike
PARI
THE IMPORTANCE OF MESH NEBULISER CONFIGURATION IN mRNA-LNP DELIVERY PERFORMANCE
Hanna Beike and Dr Benjamin Heine highlight the superior performance of customisable drug-specific nebuliser platforms, such as eFlowM
®
Open System and eFlow
®
Integrated, for the delivery of messenger RNA-based inhalation therapies.
EXPERT VIEW
Dr Fiona McLaughlin
IMPROVING RNA THERAPEUTIC TARGETING BEYOND DELIVERY
Dr Fiona McLaughlin and Dr Mark Edbrooke discuss the possibilities for developing novel cancer treatments using functionalised nanoparticles, in order to transport a variety of therapies into the tumour microenvironment.
EXPERT VIEW
Dr Max Chambers
REVEALING THE FRONTIER: DRUG DELIVERY CHALLENGES AND INNOVATIONS IN OCULAR GENE THERAPY
Dr Max Chambers discusses novel approaches for delivering ocular gene therapies, summarising the challenges and benefits of various delivery routes and exploring the devices used to successfully improve vision.
EARLY INSIGHT
Professor Steven Gill
Neurochase
PRECISION DELIVERY: SEAMLESS COLLABORATION FOR DELIVERING NEURO-THERAPEUTICS
Professor Steven Gill and Alan Suttie provide insight into the unique collaboration and design philosophy behind their novel scalable interventional delivery system for gene and cell therapies – the Neurochase Acute Drug Delivery System.
EXPERT VIEW
Bharat Arora
DRUG DELIVERY IN CELL AND GENE THERAPY: WHY EARLY DEVICE DEVELOPMENT MATTERS
Bharat Arora discusses how the delivery method for a cell and gene therapy is an integral part of the overall product, inextricable from the therapy itself, and how properly synchronising drug and delivery device development can greatly benefit the overall development programme.
EXPERT VIEW
Dr Akshay Peer
CELL AND GENE THERAPY DIGITAL INFRASTRUCTURE: REPLACING FRAGMENTATION WITH STANDARDISATION
Dr Akshay Peer examines why bespoke digital systems for cell and gene therapies are reaching a saturation point, how clinicians experience this fragmentation on the ground and why a shift towards standardisation is becoming essential for enabling safe, scalable and sustainable delivery of these innovative treatments.
EXPERT VIEW
Dr Elodie Bovier
MAPPING INNOVATION IN mRNA DELIVERY THROUGH PATENT TRENDS
Dr Elodie Bovier considers the evolution of messenger RNA therapeutics in biotechnology, examining patent trends and exploring how they have triggered litigation in the field, demonstrating the growth and maturity of this sector.
EXPERT VIEW
Dr Ethan Miller
SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION
Dr Ethan Miller examines the manufacturing of cell and gene therapies where shear stress can impact cells and explores strategies to mitigate such damage, helping to ensure that therapies retain their viability, functionality and therapeutic potency from production through to administration.
EXPERT VIEW
Jessica Alzamora
PRECISION DELIVERY: THE MISSING LINK IN CELL & GENE THERAPY
Jessica Alzamora, Dr Karla Sanchez and Emily Chang discuss the necessity for precision when delivering cell and gene therapies, explore how this precision can be designed and demonstrated, then go on to describe how a minimum viable product approach to device development can act as a strong predictor of a successful delivery device.
EXPERT VIEW
Alejandra Sanchez
DRUG DELIVERY DEVICE INNOVATION IN CELL AND GENE THERAPIES
Dr Alejandra Sanchez and Charlie Dean consider the evolution of drug delivery technologies and how cell and gene therapies are showing promise as a new class of medicine to correct disease at its source.
Top
